Dr. David Andrews

AstraZeneca

Inhibiting protein:protein interactions: A new approach to small molecule drug discovery

Dr. David Andrews, Director of the Pre-Clinical Scientific Alliance, AstraZeneca, discusses the work of the Perturbation of Protein-Protein Interactions (PoPPI) program, a collaboration between AstraZeneca, the University of Leeds, University of Bristol, Northern Institute for Cancer Research and Domainex. Hear how the researchers working on this program are developing computational and chemical tools to design and synthesize new small molecule drugs that will target specific binding sites for selective inhibition of protein-protein interactions and how this approach may help develop new treatments for diseases, such as Leukemia.

LIKE 1


Dr. David Andrews
ELRIG

Dr. David Andrews

Biography

Director of the Pre-Clinical Scientific Alliance More
Follow David

Dr. David Andrews

AstraZeneca

Dr David Andrews trained as a pharmacist at Nottingham University and then as a PhD organic chemist at Liverpool University. From 1990-2003, he held positions at GlaxoSmithKline as a medicinal chemist, project leader and department director. Since 2003, he has worked as an Associate Director in the Oncology iMed Chemistry Department of AstraZeneca. He has experience of working in CNS, inflammation, antiviral and oncology discovery and development chemistry. He currently leads AstraZeneca's Oncology lead identification chemistry group and is accountable for many of its discovery chemistry externalization and project collaboration activities.